Fotantinib/Fotantinib side effects and treatments

Fostamatinib is a SYK (spleen tyrosine kinase) inhibitor. Its core mechanism is to reduce the destruction of platelets by the autoimmune system by inhibiting the B cell signaling pathway. Although the drug is highly effective, it may be accompanied by a range of manageable side effects. Overseas studies show that the most common reactions include increased blood pressure, diarrhea, abnormal liver function, and mild fatigue. These are usually dose-related and can be controlled by adjusting the dose or adjuvant treatment in most cases.

Patients may experience mild to moderate digestive discomfort, such as diarrhea or nausea during initial use. Doctors usually recommend that patients maintain adequate fluid intake and use antidiarrheal medications when necessary. If symptoms persist or worsen, short-term discontinuation of the drug and clinical evaluation should be considered. Increased blood pressure is one of the more common adverse reactions. It is recommended to monitor blood pressure regularly during the initial treatment and dose adjustment stages, and use antihypertensive drugs to assist control if necessary. In addition, elevated liver function indicators may also occur in some patients, especially when combined with other drug treatments. Regular detection of liver enzyme levels is a necessary management tool. Once a significant increase is found, the medication regimen should be adjusted under the guidance of a doctor.

Some patients report mild headache, fatigue or loss of appetite. These are reversible reactions and generally do not affect long-term treatment. For long-term users, doctors may recommend rechecking blood routine and liver and kidney function every 4 to 6 weeks to detect abnormalities in time. It is worth noting that the metabolic pathway of fostatinib involves the liver enzyme CYP system, so interactions with other drugs also need to be paid attention to. Patients should inform their doctor when taking other drugs (such as anticoagulants, antihypertensive drugs, etc.) to avoid drug overlap or metabolic interference.

Overall, most of the adverse reactions of fostatinib are mild to moderate and can be effectively controlled through monitoring and dose adjustment.

Reference materials:https://go.drugbank.com/drugs/DB12010